• SR-202 (PPAR antagonist) for Reliable Cell Assays

  2026-09-10

  A scenario-based guide to using SR-202 (PPAR antagonist), SKU B6929, to separate PPARγ-dependent biology from nonspecific loss of cell viability. It covers assay controls, formulation, interpretation, and practical vendor-selection criteria for metabolic and immunometabolic research.

• mPROSS Raises Functional Kv Channel Expression

  2026-09-10

  The reference study introduces mPROSS, an automated design method that combines phylogenetic information with atomistic energy calculations to improve membrane-protein expression in a single design cycle. Applied to a Kv1.2–Kv2.1 paddle chimera, the method produced functional variants with up to a 14-fold increase in whole-cell current density without measurably changing single-channel conductance or opening probability.

• L-Ornithine as a Liver–Brain Axis Probe

  2026-09-09

  L-Ornithine is more than a urea cycle intermediate: it can function as a controlled perturbation for connecting hepatic ammonia handling with astrocyte metabolism. This article translates recent OTC–ornithine findings into assay-design decisions, controls, and interpretation limits for amino acid metabolism research.

• Geneticin: From Selection to Translational Insight

  2026-09-09

  A thought-leadership guide to using Geneticin and G418 Sulfate as controlled experimental tools across stable cell-line development, Dengue virus research, and mechanistic cancer biology—while separating validated evidence from translational inference.

• Urolithin A Workflows for Mitochondrial Research

  2026-09-08

  Build reproducible Urolithin A experiments around mitophagy, mitochondrial respiration, inflammation, and fibrosis-relevant metabolic readouts. This workflow connects mitochondrial quality control with the glutamine–GDH–SIRT4 axis while clearly separating established evidence from testable extensions.

• Praeruptorin A: From Pathway to Translation

  2026-09-07

  Praeruptorin A is an angular pyranocoumarin compound with a differentiated translational profile spanning ferroptosis, inflammation, cardiomyopathy research, and hepatocellular carcinoma cell invasion. This evidence-led perspective connects mechanism, assay design, product handling, and development strategy without overstating preclinical findings as clinical proof.

• Verbascoside for PKC/NF-κB Signaling Studies

  2026-09-07

  Verbascoside is a practical small-molecule probe for separating PKC/NF-κB pathway effects from broader changes in osteoclast differentiation and inflammatory signaling. This workflow connects its validated activity in RANKL-stimulated macrophage models with the PTX3–TLR4/NF-κB–FGF21 axis described in recent bone research, while emphasizing controls, timing, and assay interpretation.

• 2-D08: A Precision Probe for SUMO Transfer

  2026-09-05

  2-D08 (2’,3’,4’-trihydroxyflavone) is a mechanistically selective probe for studying substrate-level SUMO transfer. This article connects its cancer-cell evidence with the ETS1–SENP2–FUNDC1 mitophagy pathway while defining practical assay boundaries and translational limitations.

• MK 0893: Discovery of a Potent Glucagon Receptor Antagonist

  2026-09-05

  The reference study describes MK 0893 as a potent, reversible, and competitive glucagon receptor antagonist developed through optimization of a pyrazole-based lead. Its nanomolar receptor and cAMP activity, family B GPCR selectivity, and glucose-lowering effects in human GCGR mouse models supported advancement into further preclinical and clinical evaluation.

• EdU Flow Cytometry Assay Kits (Cy5) for S-Phase

  2026-09-04

  EdU Flow Cytometry Assay Kits (Cy5) turn DNA replication into a quantitative, multiplexable flow-cytometry endpoint without harsh BrdU denaturation. This practical guide shows how to apply the assay to colorectal cancer models, drug-response studies, genotoxicity testing, and immune-metabolism experiments inspired by recent findings on serine/glycine restriction.

• MLF2, USP7, and p53 in Colorectal Cancer

  2026-09-04

  The reference study identifies MLF2 as a negative regulator of p53 that interferes with USP7-mediated p53 deubiquitination, helping explain how colorectal tumors with wild-type p53 can suppress its activity. Its interaction, ubiquitination, functional, and clinical analyses position the MLF2–p53 axis as a mechanistically relevant route to colorectal carcinogenesis and a useful framework for protease-sensitive protein studies.

• Perphenazine: D2 Antagonism and Research Uses

  2026-09-03

  Perphenazine is a dopamine D2 receptor antagonist with additional histamine, muscarinic, and adrenergic receptor activity. Research data support its use in schizophrenia research, mitochondria-mediated cell death induction, opioid tolerance suppression, and host-directed antibacterial studies, but these findings remain model- and condition-dependent.

• CUDC-907: Dual PI3K/HDAC Workflow Guide

  2026-09-02

  CUDC-907 is a dual PI3K and HDAC inhibitor for controlled in vitro studies of PI3K/AKT signaling, histone acetylation, cell-cycle behavior, and apoptosis. It is intended for scientific research only; it should not be used for diagnosis, treatment, or clinical decision-making.

• WY-14643 Workflow for PPARα Metabolic Studies

  2026-09-02

  Build clearer PPARα experiments with WY-14643 (Pirinixic Acid), from soluble stock preparation to receptor-linked lipid and inflammatory readouts. The workflow distinguishes direct agonist benchmarking from environmental toxicology, helping researchers interpret metabolic, endothelial, and omics data with greater confidence.

• Gap26: Connexin 43 Mimetic Peptide in Cell Assays

  2026-09-02

  Gap26 provides a practical way to interrogate connexin 43-dependent calcium waves, ATP release, and intercellular communication. This guide connects validated peptide conditions with vascular smooth muscle research and a new mitochondrial-transfer asthma study, while emphasizing controls and interpretation limits.

8364 records 1/558 page Next 12345 下5页 Last page